A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn’s Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease

Abstract Background and Aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn’s disease [CD]. Methods...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of Crohn's and colitis 2019-02, Vol.13 (2), p.209-217
Hauptverfasser:	Macaluso, Fabio Salvatore, Fries, Walter, Privitera, Antonio Carlo, Cappello, Maria, Siringo, Sebastiano, Inserra, Gaetano, Magnano, Antonio, Di Mitri, Roberto, Mocciaro, Filippo, Belluardo, Nunzio, Scarpulla, Giuseppe, Magrì, Giovanni, Trovatello, Antonino, Carroccio, Antonio, Genova, Salvatore, Bertolami, Carmelo, Vassallo, Roberto, Romano, Claudio, Citrano, Michele, Accomando, Salvatore, Ventimiglia, Marco, Renna, Sara, Orlando, Rosalba, Rizzuto, Giulia, Porcari, Serena, Ferracane, Concetta, Cottone, Mario, Orlando, Ambrogio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - therapeutic use Adult Crohn Disease - drug therapy Female Gastrointestinal Agents - therapeutic use Humans Infliximab - therapeutic use Male Propensity Score Sicily Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!